Kane Biotech was preparing the annual financial statements and, as part of th prepared the following alphabetized schedule based on adjusted values at D calculations. Round final answers to nearest whole dollar.) Asset Equipment Furniture Land office building Warehouse Usef 7,90 8 Date of Purchase May 1/15 Jun. 28/15 Apr. 5/15 Apr. 5/15 Apr. 5/15 Deprec. Method Units DDB N/A SL SL Residual Value $ 2,390 2,900 N/A 25,100 19,000 Cost $ 49,000 21,000 94,000 95,000 68,500 1 2 *DDB = Double-declining-balance; SL = Straight-line; Units = Units-of-produc inancial statements and, as part of the year-end procedures, assessed the assets and edule based on adjusted values at December 31, 2020: (Do not round intermediate arest whole dollar.) rec. hod its Useful Life 7,900 units DB 8 yrs Residual Value $ 2,390 2,900 N/A 25,100 19,000 Cost $ 49,000 21,000 94,000 95,000 68,500 Accum. Deprec. $ 28,910 17,339 N/A 31,100 21,938 Recoverable Amount $ 5,390 3,850 110,800 61,500 54,100 N/A 15 yrs 20 yrs craight-line; Units = Units-of-production: N/A = Not applicable Required: 1. Record any impairment losses at December 31, 2020. Assume Kane Biotech has recorded View transaction list View journal entry worksheet No Date General Journal 1 Dec 31, 2020 Impairment loss Saved Help Save & E 0. Assume Kane Biotech has recorded no impairment losses in previous years. eneral Journal Debit Credit Saved 2. Record depreciation for each asset at December 31, 2021. Assume that there was no change in th regardless of any impairment losses that might have occurred. The equipment produced 2,250 units View transaction list Journal entry worksheet 1 2 3 4 > 31, 2021. Assume that there was no change in the residual values or useful lives e occurred. The equipment produced 2,250 units during 2021. >